Aligos (ALGS): Nilai Total Aset Perusahaan

Aligos Therapeutics (ALGS) develops antiviral agents by optimizing the logistics of chemical components to protect margins and clinical timelines. Current financial health relies on liquidity, as cash flow remains negative due to the absence of commercial products. The price action of total assets on GURU.Markets stands at 100.52, confirming a trajectory toward leadership in hepatitis B and NASH therapy through innovative small molecules.

Total assets are calculated inversely via return on assets (ROA), summing equity and liabilities to determine the organization's aggregate resource potential. Gross asset dynamics are critical for Aligos Therapeutics (ALGS), as the high capital intensity of developing NASH drugs requires a constant influx of funds, where growth in these metrics may indicate either investment development or an increase in the debt load.